Neoadjuvant immunotherapy for localized non-small cell lung cancer with rare mutations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase II, single-arm, open-label study evaluates the clinical feasibility and safety of administering three cycles of Toripalimab combined with chemotherapy in patients with localized non-small cell lung cancer (NSCLC) harboring rare mutations. A total of 30 eligible patients will receive treatment, and dynamic blood samples will be collected for exploratory analysis. The primary goal is to achieve a pathological complete response, defined as no residual tumor in the primary lung cancer and metastatic lymph nodes. Following treatment, patients may receive optional adjuvant therapy based on the investigators' discretion.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age: 18 Years and older
2. ECOG physical score 0-1 points; expected survival time ≥ 3 months;
3. Pathologically confirmed diagnosis with Stage IIB-IIIB NSCLC which harbored rare driver alteration including RET fusions, BRAF (V600E or non-V600E but confirmed driver mutations), ERBB2 exon20 insertion, MET amplification (FISH confirmed) or exon 14 skipping. Suspected N2 disease should be confirmed by either mediastinoscopy or EBUS. N1 disease could be determined through PET/CT but biopsy of primary lung cancer is needed;
4. Lung function capacity capable of tolerating the proposed lung surgery
5. Available tissue of tumor for PD-L1 test
6. Subjects voluntarily joined the study and signed informed consent, with good compliance to follow-up.

Exclusion Criteria:

1. Stage I and stage IV NSCLC;
2. Patients who have previously used any other anti-tumor drugs or radiotherapy;
3. Large panel NGS indicated sensitive EGFR alteration, ALK fusion, ROS1 fusion or any other driver mutations combined with MDM2/MDM4 amplification;
4. Histologically confirmed small cell lung cancer (including lung cancer mixed with small cell lung cancer and non-small cell lung cancer);
5. A history of active bleeding within the 6 months before enrollment, or receiving thrombolysis or anticoagulant therapy, or the investigator believes that there is a clear tendency to gastrointestinal bleeding (such as esophageal varices with bleeding risk, local activity) Ulcer lesions, etc.) or active hemoptysis;
6. Patients with any underlying disease that investigators consider it may affect patient's prognosis including sever cardiovascular, pulmonary disease or serious infections; Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or patients with total gastrectomy;
7. Known or suspected autoimmune disease with activity. Participants may be enrolled if they have type 1 diabetes, hypothyroidism that requires only hormone replacement therapy, skin diseases that require no systemic treatment (such as purpura, psoriasis, or hair loss), or other conditions that are not expected to return without external trigger.
8. Patients with active hepatitis B (positive for HBsAg) or hepatitis C (positive for HCV RNA).
9. Patients with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)
10. Patients with other active malignancies within five years
11. Pregnant or lactating women; those who have fertility are unwilling or unable to take effective contraceptive measures;
12. Patients with low compliance or willingness to take the drugs and surveillance.

Where it's running

• Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences
  Guanzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Wen-Zhao Zhong, Ph.D
• Email: syzhongwenzhao@scut.edu.cn
• Phone: +86 02083827812

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing ZM008 alone and with Pembrolizumab in patients with advanced solid tumors

  This study is testing a new treatment called ZM008, alone and with another drug called Pembrolizumab, to see if it can help patients with advanced solid tumors who have run out of other treatment options.

  Recruiting at 3 sites Phase 1 Zumutor Biologics Inc. · Boston, Massachusetts and 2 other locations · NCT06451497

• Combining Toripalimab with Cryoablation for Advanced Lung Cancer Treatment

  This study is testing if combining a new immune therapy called toripalimab with a freezing treatment can help people with advanced lung cancer who have had limited growth after their first treatment.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality and 2 other locations · NCT06127303

• Combining LMV-12 with Osimertinib for advanced lung cancer

  This study is testing a new treatment combining LMV-12 with osimertinib to see if it can help people with advanced lung cancer who haven't responded to other treatments.

  Recruiting Phase 1/2 Hunan Province Tumor Hospital · Changsha, Hunan · NCT06109558

• Evaluating BDTX-4933 for patients with specific cancer mutations

  This study is testing a new drug called BDTX-4933 to see if it can help adults with advanced cancers that have certain gene mutations feel better and improve their treatment options.

  Recruiting at 34 sites Phase 1/2 Servier · Gilbert, Arizona and 48 other locations · NCT05786924

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.